Weekly Research Analysts’ Ratings Updates for Artiva Biotherapeutics (ARTV)

Artiva Biotherapeutics (NASDAQ: ARTV) recently received a number of ratings updates from brokerages and research firms:

• 5/26/2026 – Artiva Biotherapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 5/17/2026 – Artiva Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/12/2026 – Artiva Biotherapeutics had its price target raised by Needham & Company LLC from $18.00 to $41.00. They now have a “buy” rating on the stock.
• 5/11/2026 – Artiva Biotherapeutics had its price target raised by Cantor Fitzgerald from $10.00 to $40.00. They now have an “overweight” rating on the stock.
• 5/11/2026 – Artiva Biotherapeutics had its price target raised by Wedbush from $23.00 to $40.00. They now have an “outperform” rating on the stock.
• 5/9/2026 – Artiva Biotherapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Artiva Biotherapeutics had its price target raised by HC Wainwright from $15.00 to $35.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Artiva Biotherapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $18.00 price target on the stock.
• 4/28/2026 – Artiva Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/24/2026 – Artiva Biotherapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/20/2026 – Artiva Biotherapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/12/2026 – Artiva Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/4/2026 – Artiva Biotherapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling at Artiva Biotherapeutics

In other news, COO Jennifer Bush sold 8,790 shares of Artiva Biotherapeutics stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $79,197.90. Following the sale, the chief operating officer directly owned 337,920 shares of the company’s stock, valued at approximately $3,044,659.20. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Horan sold 7,002 shares of Artiva Biotherapeutics stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $63,088.02. Following the sale, the insider directly owned 293,450 shares in the company, valued at $2,643,984.50. The trade was a 2.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 53,040 shares of company stock worth $477,890 over the last three months. 21.40% of the stock is owned by corporate insiders.

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.